about
Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard StudyA randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST studyRaltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionChanges in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudinePredictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudineDetermination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South AfricaBiomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control studyPredictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).Plasma levels of soluble CD14 independently predict mortality in HIV infection.HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialHip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudineAssessing site performance in the Altair study, a multinational clinical trialDifferences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART.Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples.Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control StudyPharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 studyAn HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.Therapeutic vaccination against HIV: current progress and future possibilities.Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyPredictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database.Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimenShort communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting.Project Phidisa: development of clinical research capacity within the South African National Defence Force.Antiretroviral roll-out: the problem of second-line therapy.Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.
P50
Q27690715-AC818A1F-801B-4B41-844B-497A89F1F9C3Q28469017-F885463B-BD6D-4A7F-8A3E-BDB5372CEAB4Q28469027-9A8C0B4E-6728-4CEC-9145-BE89D7CF14AEQ28543732-5F582D80-BA0D-4510-9980-27B9571D9673Q28728374-894C8241-73B3-4A0E-84CD-0A5D5E0EC258Q28743352-4FF3B024-8865-45CE-80B0-2865C1CA8ED5Q31150412-1639E48B-A449-439F-A617-75583955EC9CQ31154955-494222CB-186F-4FF2-84A0-B7D59A3ECED0Q33671152-6ED212B0-5AF5-4E43-94F0-4193D7AFCB6AQ33987654-C6038B07-AFF7-4AFA-B383-8039ABDE2A4AQ34011661-F5E0EC0D-D6D6-4047-BBC9-21B9FC572269Q34431819-34E9461B-39D8-41D4-BF49-AA5F63E99AE9Q34485916-0F76E5C1-8515-4A7A-B76E-92059C9746B4Q34606231-DE67254C-F3FF-4B91-BE2B-DFD5FCEF4ED0Q34606647-1C7CEFAF-4694-473F-8345-6CE7E87789B5Q34625248-5D723501-8E3B-46B2-8182-B49184012687Q34764002-DFA7B67E-60CA-42FD-A1C5-B3D280EE7025Q35035055-75BD2F88-9CCF-4CF6-B36B-0167B7D86576Q35124897-147D360B-DF33-4153-A658-421261D1BE22Q35145668-FC8E8013-5AF1-4A8A-83BC-A118A6F41555Q35545972-7111CC50-4429-4B13-85BF-002732392A79Q35568896-804E661D-D842-480B-B329-0FC70A35E000Q35602870-DBC22B22-5312-4AE2-AC89-464FCB189BD7Q35635848-3B25AD74-7EE0-49DD-847E-D57949AD12EBQ35806035-1A9EE368-8B14-48BD-A2FC-857802C9C2E0Q35806474-B7BA1EA3-9FB0-4F23-834E-BE08F1BA51BFQ35878653-2B8C2B0D-27CB-4CB5-A465-E9ED38F199A7Q36334994-73DB4FAC-8503-49E3-B106-C78A546C896DQ36554279-2D5FA902-A89B-4C67-A331-147AFE74FBA3Q36676533-910FEBD0-55BC-48C7-9272-A7CBAB302082Q36875697-F165353C-0ABE-4F43-9399-A069E95762EAQ37026878-287FA81A-6650-4D67-AA73-2AD4308EF66AQ37028220-2ED25B1D-E43F-46F3-AE83-3EE45AD6E805Q37272765-24759617-2323-44E8-9746-E1733A7A6AA8Q37351208-44900D88-9B1A-4363-B8F0-ABAC1E8C9896Q37359256-E7AC79F9-8FDE-4F94-B743-E62B6998B19DQ37447162-4B019045-7E2A-4147-816E-F062C4324D34Q37555574-C3114308-EE8E-4F27-82A4-21D2D32834FBQ37613840-EA078B98-3802-45CA-8CFC-234C9B6D1D2BQ37641267-EE8BD437-2A4F-4167-B392-CAA46AF5B3F0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sean Emery
@ast
Sean Emery
@en
Sean Emery
@es
Sean Emery
@nl
Sean Emery
@sl
type
label
Sean Emery
@ast
Sean Emery
@en
Sean Emery
@es
Sean Emery
@nl
Sean Emery
@sl
prefLabel
Sean Emery
@ast
Sean Emery
@en
Sean Emery
@es
Sean Emery
@nl
Sean Emery
@sl
P108
P1053
H-4920-2013
J-3825-2017
P106
P21
P31
P496
0000-0001-6072-8309